Good Life Advisors LLC Buys 1,030 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Good Life Advisors LLC lifted its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 17.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,073 shares of the medical equipment provider's stock after purchasing an additional 1,030 shares during the period. Good Life Advisors LLC's holdings in Intuitive Surgical were worth $3,503,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. Onefund LLC boosted its stake in Intuitive Surgical by 1.9% in the 4th quarter. Onefund LLC now owns 947 shares of the medical equipment provider's stock worth $494,000 after purchasing an additional 18 shares during the period. AlphaCore Capital LLC boosted its position in shares of Intuitive Surgical by 4.2% in the fourth quarter. AlphaCore Capital LLC now owns 451 shares of the medical equipment provider's stock worth $235,000 after buying an additional 18 shares during the period. Parkside Financial Bank & Trust boosted its position in shares of Intuitive Surgical by 2.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 747 shares of the medical equipment provider's stock worth $390,000 after buying an additional 19 shares during the period. Accredited Investors Inc. grew its holdings in shares of Intuitive Surgical by 1.9% during the fourth quarter. Accredited Investors Inc. now owns 1,040 shares of the medical equipment provider's stock valued at $543,000 after buying an additional 19 shares in the last quarter. Finally, Second Line Capital LLC raised its position in Intuitive Surgical by 3.4% during the fourth quarter. Second Line Capital LLC now owns 578 shares of the medical equipment provider's stock valued at $302,000 after buying an additional 19 shares during the period. 83.64% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

ISRG has been the subject of a number of research reports. Royal Bank Of Canada decreased their price objective on Intuitive Surgical from $630.00 to $605.00 and set an "outperform" rating for the company in a research report on Wednesday, April 23rd. Piper Sandler decreased their price target on shares of Intuitive Surgical from $670.00 to $575.00 and set an "overweight" rating for the company in a report on Wednesday, April 23rd. Robert W. Baird lowered their price objective on shares of Intuitive Surgical from $600.00 to $575.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 23rd. Erste Group Bank upgraded shares of Intuitive Surgical from a "hold" rating to a "buy" rating in a research note on Thursday, June 5th. Finally, BTIG Research set a $560.00 target price on shares of Intuitive Surgical and gave the company a "buy" rating in a research note on Monday, April 14th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $588.95.

Intuitive Surgical Stock Down 0.5%

NASDAQ:ISRG traded down $2.62 during trading hours on Thursday, hitting $509.49. 1,173,748 shares of the stock were exchanged, compared to its average volume of 1,675,866. The company has a market capitalization of $182.61 billion, a P/E ratio of 74.71, a price-to-earnings-growth ratio of 5.43 and a beta of 1.67. The company's 50 day moving average is $527.31 and its two-hundred day moving average is $537.92. Intuitive Surgical, Inc. has a twelve month low of $413.82 and a twelve month high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its quarterly earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.71 by $0.10. The business had revenue of $2.25 billion for the quarter, compared to analysts' expectations of $2.19 billion. Intuitive Surgical had a return on equity of 14.43% and a net margin of 28.41%. During the same quarter last year, the business earned $1.50 earnings per share. On average, equities research analysts expect that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Insider Transactions at Intuitive Surgical

In related news, EVP Gary Loeb sold 1,700 shares of the firm's stock in a transaction on Friday, April 25th. The stock was sold at an average price of $513.18, for a total transaction of $872,406.00. Following the sale, the executive vice president now owns 2,245 shares of the company's stock, valued at approximately $1,152,089.10. This trade represents a 43.09% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Robert Desantis sold 188 shares of the business's stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $515.91, for a total value of $96,991.08. Following the completion of the transaction, the executive vice president now owns 5,224 shares of the company's stock, valued at $2,695,113.84. This represents a 3.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 4,998 shares of company stock worth $2,611,577 in the last quarter. 0.70% of the stock is owned by company insiders.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.